{"transactions":[{"id":743666,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-10T20:45:11.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":10200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest in full on the earliest of (i) June 9, 2027, (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, or (iii) a \"Change in Control\" (as defined in the Issuer's 2024 Equity Incentive Plan) of the Issuer, subject in each case, to the Reporting Person providing continuous service to the Issuer on each such date."}],"balance_after":10200,"derivative":{"exercise_price":28.56,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":10200},"source":{"system":"sec-edgar","filing":"0001055624-26-000003","document":"form4-06102026_040607.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000105562426000003/form4-06102026_040607.xml","form_type":"4"}},{"id":947732,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-06T21:18:13.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":7800,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":7800,"derivative":{"exercise_price":6.76,"exercise_date":"2027-01-02","expiration_date":"2036-01-01","underlying":"Common  Stock","underlying_shares":7800},"source":{"system":"sec-edgar","filing":"0001453687-26-000029","document":"wk-form4_1767734290.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368726000029/wk-form4_1767734290.xml","form_type":"4"}},{"id":947731,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-06T21:18:13.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":2600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2027."}],"balance_after":8646285,"source":{"system":"sec-edgar","filing":"0001453687-26-000029","document":"wk-form4_1767734290.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368726000029/wk-form4_1767734290.xml","form_type":"4"}},{"id":1115471,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-11T20:30:21.000Z","date":"2025-06-09","kind":"grant","planned":false,"acquired":true,"shares":10200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest in full on the earliest of (i) June 9, 2026, (ii) the date of the Issuer's 2026 Annual Meeting of stockholders, or (iii) a \"Change in Control\" (as defined in the Issuer's 2024 Equity Incentive Plan) of the Issuer, subject in each case, to the Reporting Person providing continuous service to the Issuer on each such date."}],"balance_after":10200,"derivative":{"exercise_price":24.48,"expiration_date":"2035-06-08","underlying":"Common Stock","underlying_shares":10200},"source":{"system":"sec-edgar","filing":"0001415889-25-016672","document":"form4-06112025_040604.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000141588925016672/form4-06112025_040604.xml","form_type":"4"}},{"id":1173546,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-11T22:12:08.000Z","date":"2025-04-11","kind":"purchase","planned":false,"acquired":true,"shares":53706,"price":16.31,"value":875944.86,"ownership":{"direct":false,"nature":"By LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $15.96 to $16.68 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares are held by TAS Partners LLC (\"TAS\"). The Reporting Person is the sole managing member of TAS and, as such, has sole voting and dispositive power over the shares held by TAS. The Reporting Person disclaims beneficial ownership of the shares held by TAS except to the extent of his pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."}],"balance_after":1503358,"source":{"system":"sec-edgar","filing":"0001415889-25-010588","document":"form4-04112025_100403.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000141588925010588/form4-04112025_100403.xml","form_type":"4"}},{"id":1173545,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-11T22:12:08.000Z","date":"2025-04-10","kind":"purchase","planned":false,"acquired":true,"shares":45858,"price":16.73,"value":767204.34,"ownership":{"direct":false,"nature":"By LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $16.29 to $17.00 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares are held by TAS Partners LLC (\"TAS\"). The Reporting Person is the sole managing member of TAS and, as such, has sole voting and dispositive power over the shares held by TAS. The Reporting Person disclaims beneficial ownership of the shares held by TAS except to the extent of his pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."}],"balance_after":1449652,"source":{"system":"sec-edgar","filing":"0001415889-25-010588","document":"form4-04112025_100403.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000141588925010588/form4-04112025_100403.xml","form_type":"4"}},{"id":1173544,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-11T22:12:08.000Z","date":"2025-04-09","kind":"purchase","planned":false,"acquired":true,"shares":4856,"price":15.23,"value":73956.88,"ownership":{"direct":false,"nature":"By LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $15.1994 to $15.2452 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares are held by TAS Partners LLC (\"TAS\"). The Reporting Person is the sole managing member of TAS and, as such, has sole voting and dispositive power over the shares held by TAS. The Reporting Person disclaims beneficial ownership of the shares held by TAS except to the extent of his pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."}],"balance_after":1403794,"source":{"system":"sec-edgar","filing":"0001415889-25-010588","document":"form4-04112025_100403.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000141588925010588/form4-04112025_100403.xml","form_type":"4"}},{"id":1173543,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-11T22:12:08.000Z","date":"2025-04-09","kind":"purchase","planned":false,"acquired":true,"shares":16215,"price":14.62,"value":237063.3,"ownership":{"direct":false,"nature":"By LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $13.9869 to $14.9578 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares are held by TAS Partners LLC (\"TAS\"). The Reporting Person is the sole managing member of TAS and, as such, has sole voting and dispositive power over the shares held by TAS. The Reporting Person disclaims beneficial ownership of the shares held by TAS except to the extent of his pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."}],"balance_after":1398938,"source":{"system":"sec-edgar","filing":"0001415889-25-010588","document":"form4-04112025_100403.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000141588925010588/form4-04112025_100403.xml","form_type":"4"}},{"id":1173542,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-11T22:12:08.000Z","date":"2025-04-11","kind":"purchase","planned":false,"acquired":true,"shares":9478,"price":16.31,"value":154586.18,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $15.96 to $16.68 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":4334846,"source":{"system":"sec-edgar","filing":"0001415889-25-010588","document":"form4-04112025_100403.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000141588925010588/form4-04112025_100403.xml","form_type":"4"}},{"id":1173541,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-11T22:12:08.000Z","date":"2025-04-10","kind":"purchase","planned":false,"acquired":true,"shares":8092,"price":16.73,"value":135379.16,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $16.29 to $17.00 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":4325368,"source":{"system":"sec-edgar","filing":"0001415889-25-010588","document":"form4-04112025_100403.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000141588925010588/form4-04112025_100403.xml","form_type":"4"}},{"id":1173540,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-11T22:12:08.000Z","date":"2025-04-09","kind":"purchase","planned":false,"acquired":true,"shares":857,"price":15.23,"value":13052.11,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $15.1994 to $15.2452 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":4317276,"source":{"system":"sec-edgar","filing":"0001415889-25-010588","document":"form4-04112025_100403.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000141588925010588/form4-04112025_100403.xml","form_type":"4"}},{"id":1173539,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-11T22:12:08.000Z","date":"2025-04-09","kind":"purchase","planned":false,"acquired":true,"shares":2861,"price":14.62,"value":41827.82,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $13.9869 to $14.9578 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":4316419,"source":{"system":"sec-edgar","filing":"0001415889-25-010588","document":"form4-04112025_100403.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000141588925010588/form4-04112025_100403.xml","form_type":"4"}},{"id":1173556,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-11T21:29:40.000Z","date":"2025-04-11","kind":"purchase","planned":false,"acquired":true,"shares":36338,"price":10.7726,"value":391454.7388,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $10.395 to $11.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any."}],"balance_after":656513,"source":{"system":"sec-edgar","filing":"0001453687-25-000066","document":"wk-form4_1744406973.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368725000066/wk-form4_1744406973.xml","form_type":"4"}},{"id":1173555,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-11T21:29:40.000Z","date":"2025-04-11","kind":"purchase","planned":false,"acquired":true,"shares":6412,"price":10.7726,"value":69073.9112,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $10.395 to $11.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":8643685,"source":{"system":"sec-edgar","filing":"0001453687-25-000066","document":"wk-form4_1744406973.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368725000066/wk-form4_1744406973.xml","form_type":"4"}},{"id":1173554,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-11T21:29:40.000Z","date":"2025-04-10","kind":"purchase","planned":false,"acquired":true,"shares":3451,"price":10.9231,"value":37695.6181,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any."}],"balance_after":620175,"source":{"system":"sec-edgar","filing":"0001453687-25-000066","document":"wk-form4_1744406973.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368725000066/wk-form4_1744406973.xml","form_type":"4"}},{"id":1173553,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-11T21:29:40.000Z","date":"2025-04-10","kind":"purchase","planned":false,"acquired":true,"shares":45144,"price":10.4345,"value":471055.068,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $9.918 to $10.7461. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any."}],"balance_after":616724,"source":{"system":"sec-edgar","filing":"0001453687-25-000066","document":"wk-form4_1744406973.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368725000066/wk-form4_1744406973.xml","form_type":"4"}},{"id":1173552,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-11T21:29:40.000Z","date":"2025-04-10","kind":"purchase","planned":false,"acquired":true,"shares":609,"price":10.9231,"value":6652.1679,"ownership":{"direct":true},"balance_after":8637273,"source":{"system":"sec-edgar","filing":"0001453687-25-000066","document":"wk-form4_1744406973.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368725000066/wk-form4_1744406973.xml","form_type":"4"}},{"id":1173551,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-11T21:29:40.000Z","date":"2025-04-10","kind":"purchase","planned":false,"acquired":true,"shares":7966,"price":10.4345,"value":83121.227,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $9.918 to $10.7461. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":8636664,"source":{"system":"sec-edgar","filing":"0001453687-25-000066","document":"wk-form4_1744406973.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368725000066/wk-form4_1744406973.xml","form_type":"4"}},{"id":1173550,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-11T21:29:40.000Z","date":"2025-04-09","kind":"purchase","planned":false,"acquired":true,"shares":178,"price":9.9509,"value":1771.2602,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $9.95 to $9.97. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any."}],"balance_after":571580,"source":{"system":"sec-edgar","filing":"0001453687-25-000066","document":"wk-form4_1744406973.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368725000066/wk-form4_1744406973.xml","form_type":"4"}},{"id":1173549,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-11T21:29:40.000Z","date":"2025-04-09","kind":"purchase","planned":false,"acquired":true,"shares":41604,"price":9.4264,"value":392175.9456,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $8.95 to $9.91. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any."}],"balance_after":571402,"source":{"system":"sec-edgar","filing":"0001453687-25-000066","document":"wk-form4_1744406973.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368725000066/wk-form4_1744406973.xml","form_type":"4"}},{"id":1173548,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-11T21:29:40.000Z","date":"2025-04-09","kind":"purchase","planned":false,"acquired":true,"shares":31,"price":9.9509,"value":308.4779,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $9.95 to $9.97. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":8628698,"source":{"system":"sec-edgar","filing":"0001453687-25-000066","document":"wk-form4_1744406973.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368725000066/wk-form4_1744406973.xml","form_type":"4"}},{"id":1173547,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-11T21:29:40.000Z","date":"2025-04-09","kind":"purchase","planned":false,"acquired":true,"shares":7342,"price":9.4264,"value":69208.6288,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $8.95 to $9.91. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":8628667,"source":{"system":"sec-edgar","filing":"0001453687-25-000066","document":"wk-form4_1744406973.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368725000066/wk-form4_1744406973.xml","form_type":"4"}},{"id":1174882,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-09T21:38:10.000Z","date":"2025-04-07","kind":"purchase","planned":false,"acquired":true,"shares":412500,"price":17.1,"value":7053750.0,"ownership":{"direct":false,"nature":"By LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are held by TAS Partners LLC (\"TAS\"). The Reporting Person is the sole managing member of TAS and, as such, has sole voting and dispositive power over the shares held by TAS. The Reporting Person disclaims beneficial ownership of the shares held by TAS except to the extent of his pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."}],"balance_after":1382723,"source":{"system":"sec-edgar","filing":"0001415889-25-010499","document":"form4-04092025_090407.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000141588925010499/form4-04092025_090407.xml","form_type":"4"}},{"id":1174881,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-09T21:38:10.000Z","date":"2025-04-07","kind":"purchase","planned":false,"acquired":true,"shares":87500,"price":17.1,"value":1496250.0,"ownership":{"direct":true},"balance_after":4313558,"source":{"system":"sec-edgar","filing":"0001415889-25-010499","document":"form4-04092025_090407.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000141588925010499/form4-04092025_090407.xml","form_type":"4"}},{"id":1196024,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-03-20T23:50:25.000Z","date":"2025-03-20","kind":"purchase","planned":false,"acquired":true,"shares":54889,"price":15.5877,"value":855593.2653,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $15.00 to $15.9222. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":8621325,"source":{"system":"sec-edgar","filing":"0001453687-25-000062","document":"wk-form4_1742514619.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368725000062/wk-form4_1742514619.xml","form_type":"4"}},{"id":1196023,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-03-20T23:50:25.000Z","date":"2025-03-19","kind":"purchase","planned":false,"acquired":true,"shares":20234,"price":14.9729,"value":302961.6586,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $14.85 to $15.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":8566436,"source":{"system":"sec-edgar","filing":"0001453687-25-000062","document":"wk-form4_1742514619.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368725000062/wk-form4_1742514619.xml","form_type":"4"}},{"id":1196022,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-03-20T23:50:25.000Z","date":"2025-03-18","kind":"purchase","planned":false,"acquired":true,"shares":14740,"price":14.4233,"value":212599.442,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $13.7242 to $14.53. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":8546202,"source":{"system":"sec-edgar","filing":"0001453687-25-000062","document":"wk-form4_1742514619.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368725000062/wk-form4_1742514619.xml","form_type":"4"}},{"id":1279145,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-02-07T21:21:19.000Z","date":"2025-02-05","kind":"purchase","planned":false,"acquired":true,"shares":660000,"price":50,"value":33000000.0,"ownership":{"direct":false,"nature":"By LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were purchased in a private placement transaction on February 5, 2025, which was previously announced on the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on February 3, 2025. These shares were offered and sold in reliance on the exemption afforded by Regulation D of the Securities Act of 1933, as amended."},{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of common stock were purchased in a private placement transaction on February 5, 2025, which was previously announced on the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on February 3, 2025. These shares were offered and sold in reliance on the exemption afforded by Regulation D of the Securities Act of 1933, as amended."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by TAS Partners LLC (\"TAS\"). The Reporting Person is the sole managing member of TAS and, as such, has sole voting and dispositive power over the shares held by TAS. The Reporting Person disclaims beneficial ownership of the shares held by TAS except to the extent of his pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."}],"balance_after":970223,"source":{"system":"sec-edgar","filing":"0001415889-25-003351","document":"form4-02072025_090214.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000141588925003351/form4-02072025_090214.xml","form_type":"4"}},{"id":1279144,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-02-07T21:21:19.000Z","date":"2025-02-05","kind":"purchase","planned":false,"acquired":true,"shares":129294,"price":54.14,"value":6999977.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were purchased in a private placement transaction on February 5, 2025, which was previously announced on the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on February 3, 2025. These shares were offered and sold in reliance on the exemption afforded by Regulation D of the Securities Act of 1933, as amended."},{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of common stock were purchased in a private placement transaction on February 5, 2025, which was previously announced on the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on February 3, 2025. These shares were offered and sold in reliance on the exemption afforded by Regulation D of the Securities Act of 1933, as amended."}],"balance_after":4226058,"source":{"system":"sec-edgar","filing":"0001415889-25-003351","document":"form4-02072025_090214.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000141588925003351/form4-02072025_090214.xml","form_type":"4"}},{"id":1302836,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-01-15T21:08:27.000Z","date":"2025-01-14","kind":"purchase","planned":false,"acquired":true,"shares":4022,"price":18,"value":72396.0,"ownership":{"direct":true},"balance_after":8531462,"source":{"system":"sec-edgar","filing":"0001453687-25-000047","document":"wk-form4_1736975300.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368725000047/wk-form4_1736975300.xml","form_type":"4"}},{"id":1302835,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-01-15T21:08:27.000Z","date":"2025-01-13","kind":"purchase","planned":false,"acquired":true,"shares":8983,"price":17.7822,"value":159737.5026,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $17.40 to $18.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":8527440,"source":{"system":"sec-edgar","filing":"0001453687-25-000047","document":"wk-form4_1736975300.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368725000047/wk-form4_1736975300.xml","form_type":"4"}},{"id":1302834,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-01-15T21:08:27.000Z","date":"2025-01-13","kind":"purchase","planned":false,"acquired":true,"shares":7962,"price":16.8576,"value":134220.2112,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $16.40 to $17.3124. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":8518457,"source":{"system":"sec-edgar","filing":"0001453687-25-000047","document":"wk-form4_1736975300.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368725000047/wk-form4_1736975300.xml","form_type":"4"}},{"id":1311552,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-06T21:19:59.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":7800,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":7800,"derivative":{"exercise_price":16.93,"exercise_date":"2026-01-02","expiration_date":"2035-01-01","underlying":"Common  Stock","underlying_shares":7800},"source":{"system":"sec-edgar","filing":"0001453687-25-000020","document":"wk-form4_1736198391.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368725000020/wk-form4_1736198391.xml","form_type":"4"}},{"id":1311551,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-01-06T21:19:59.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":2600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in full on January 2, 2026."}],"balance_after":8510495,"source":{"system":"sec-edgar","filing":"0001453687-25-000020","document":"wk-form4_1736198391.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368725000020/wk-form4_1736198391.xml","form_type":"4"}},{"id":1323270,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-12-23T22:20:43.000Z","date":"2024-12-23","kind":"purchase","planned":false,"acquired":true,"shares":5181,"price":18.9996,"value":98436.9276,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $18.98 to $19.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":8507895,"source":{"system":"sec-edgar","filing":"0001453687-24-000147","document":"wk-form4_1734992437.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368724000147/wk-form4_1734992437.xml","form_type":"4"}},{"id":1323269,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-12-23T22:20:43.000Z","date":"2024-12-20","kind":"purchase","planned":false,"acquired":true,"shares":21800,"price":18.9435,"value":412968.3,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $18.73 to $19.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":8502714,"source":{"system":"sec-edgar","filing":"0001453687-24-000147","document":"wk-form4_1734992437.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368724000147/wk-form4_1734992437.xml","form_type":"4"}},{"id":1323268,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-12-23T22:20:43.000Z","date":"2024-12-19","kind":"purchase","planned":false,"acquired":true,"shares":3376,"price":18.928,"value":63900.928,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $18.82 to $19.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":8480914,"source":{"system":"sec-edgar","filing":"0001453687-24-000147","document":"wk-form4_1734992437.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368724000147/wk-form4_1734992437.xml","form_type":"4"}},{"id":1323267,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-12-23T22:20:43.000Z","date":"2024-12-19","kind":"purchase","planned":false,"acquired":true,"shares":10529,"price":18.3496,"value":193202.9384,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $17.82 to $18.8125. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":8477538,"source":{"system":"sec-edgar","filing":"0001453687-24-000147","document":"wk-form4_1734992437.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368724000147/wk-form4_1734992437.xml","form_type":"4"}},{"id":1323266,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-12-23T22:20:43.000Z","date":"2024-12-19","kind":"purchase","planned":false,"acquired":true,"shares":11303,"price":17.3858,"value":196511.6974,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $16.81 to $17.7912. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":8467009,"source":{"system":"sec-edgar","filing":"0001453687-24-000147","document":"wk-form4_1734992437.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368724000147/wk-form4_1734992437.xml","form_type":"4"}},{"id":1362268,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-11-19T00:35:50.000Z","date":"2024-11-18","kind":"purchase","planned":false,"acquired":true,"shares":20181,"price":18.4201,"value":371736.0381,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $18.32 to $18.50. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":8455706,"source":{"system":"sec-edgar","filing":"0001453687-24-000134","document":"wk-form4_1731976543.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368724000134/wk-form4_1731976543.xml","form_type":"4"}},{"id":1362267,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-11-19T00:35:50.000Z","date":"2024-11-18","kind":"purchase","planned":false,"acquired":true,"shares":38114,"price":17.9579,"value":684447.4006,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $17.32 to $18.315. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":8435525,"source":{"system":"sec-edgar","filing":"0001453687-24-000134","document":"wk-form4_1731976543.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368724000134/wk-form4_1731976543.xml","form_type":"4"}},{"id":1362266,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-11-19T00:35:50.000Z","date":"2024-11-15","kind":"purchase","planned":false,"acquired":true,"shares":277246,"price":17.0938,"value":4739187.6748,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $16.61 to $17.25. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":8397411,"source":{"system":"sec-edgar","filing":"0001453687-24-000134","document":"wk-form4_1731976543.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368724000134/wk-form4_1731976543.xml","form_type":"4"}},{"id":1362265,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-11-19T00:35:50.000Z","date":"2024-11-14","kind":"purchase","planned":false,"acquired":true,"shares":22242,"price":16.9695,"value":377435.619,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $16.71 to $17.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":8120165,"source":{"system":"sec-edgar","filing":"0001453687-24-000134","document":"wk-form4_1731976543.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368724000134/wk-form4_1731976543.xml","form_type":"4"}},{"id":1362264,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-11-19T00:35:50.000Z","date":"2024-11-14","kind":"purchase","planned":false,"acquired":true,"shares":74157,"price":16.1916,"value":1200720.4812,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $15.65 to $16.60. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":8097923,"source":{"system":"sec-edgar","filing":"0001453687-24-000134","document":"wk-form4_1731976543.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368724000134/wk-form4_1731976543.xml","form_type":"4"}},{"id":1382091,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-24T21:04:11.000Z","date":"2024-10-22","kind":"purchase","planned":false,"acquired":true,"shares":300000,"price":33.59,"value":10077000.0,"ownership":{"direct":true},"balance_after":4096764,"source":{"system":"sec-edgar","filing":"0001415889-24-025603","document":"form4-10242024_091007.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000141588924025603/form4-10242024_091007.xml","form_type":"4"}},{"id":1390980,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2024-10-04T21:58:13.000Z","date":"2024-10-02","kind":"other","planned":false,"acquired":true,"shares":20045,"ownership":{"direct":false,"nature":"By wife"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pro rata distribution for no consideration from TAS Partners LLC to the reporting person or the reporting person's spouse, as the case may be. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pro rata distribution for no consideration from TAS Partners LLC to the reporting person or the reporting person's spouse, as the case may be. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any."}],"balance_after":20045,"derivative":{"exercise_price":46.5,"exercise_date":"2022-04-11","expiration_date":"2027-04-11","underlying":"Common  Stock","underlying_shares":20045},"source":{"system":"sec-edgar","filing":"0001453687-24-000115","document":"wk-form4_1728079086.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368724000115/wk-form4_1728079086.xml","form_type":"4"}},{"id":1390979,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2024-10-04T21:58:13.000Z","date":"2024-10-02","kind":"other","planned":false,"acquired":true,"shares":113587,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pro rata distribution for no consideration from TAS Partners LLC to the reporting person or the reporting person's spouse, as the case may be. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pro rata distribution for no consideration from TAS Partners LLC to the reporting person or the reporting person's spouse, as the case may be. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any."}],"balance_after":113587,"derivative":{"exercise_price":46.5,"exercise_date":"2022-04-11","expiration_date":"2027-04-11","underlying":"Common  Stock","underlying_shares":113587},"source":{"system":"sec-edgar","filing":"0001453687-24-000115","document":"wk-form4_1728079086.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368724000115/wk-form4_1728079086.xml","form_type":"4"}},{"id":1390978,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2024-10-04T21:58:13.000Z","date":"2024-10-02","kind":"other","planned":false,"acquired":false,"shares":133632,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pro rata distribution for no consideration from TAS Partners LLC to the reporting person or the reporting person's spouse, as the case may be. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pro rata distribution for no consideration from TAS Partners LLC to the reporting person or the reporting person's spouse, as the case may be. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any."}],"balance_after":33408,"derivative":{"exercise_price":46.5,"exercise_date":"2022-04-11","expiration_date":"2027-04-11","underlying":"Common Stock","underlying_shares":133632},"source":{"system":"sec-edgar","filing":"0001453687-24-000115","document":"wk-form4_1728079086.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368724000115/wk-form4_1728079086.xml","form_type":"4"}},{"id":1390977,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-04T21:58:13.000Z","date":"2024-10-04","kind":"purchase","planned":false,"acquired":true,"shares":4879,"price":23.933,"value":116769.107,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $23.87 to $24.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":8023766,"source":{"system":"sec-edgar","filing":"0001453687-24-000115","document":"wk-form4_1728079086.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368724000115/wk-form4_1728079086.xml","form_type":"4"}},{"id":1390976,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-04T21:58:13.000Z","date":"2024-10-04","kind":"purchase","planned":false,"acquired":true,"shares":16650,"price":23.5659,"value":392372.235,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $22.87 to $23.8699. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":8018887,"source":{"system":"sec-edgar","filing":"0001453687-24-000115","document":"wk-form4_1728079086.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368724000115/wk-form4_1728079086.xml","form_type":"4"}},{"id":1390975,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-04T21:58:13.000Z","date":"2024-10-04","kind":"purchase","planned":false,"acquired":true,"shares":48880,"price":22.3542,"value":1092673.296,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $21.87 to $22.8626. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":8002237,"source":{"system":"sec-edgar","filing":"0001453687-24-000115","document":"wk-form4_1728079086.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368724000115/wk-form4_1728079086.xml","form_type":"4"}},{"id":1390974,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-04T21:58:13.000Z","date":"2024-10-04","kind":"purchase","planned":false,"acquired":true,"shares":9892,"price":21.3501,"value":211195.1892,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $20.87 to $21.86. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":7953357,"source":{"system":"sec-edgar","filing":"0001453687-24-000115","document":"wk-form4_1728079086.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368724000115/wk-form4_1728079086.xml","form_type":"4"}},{"id":1390973,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-04T21:58:13.000Z","date":"2024-10-03","kind":"purchase","planned":false,"acquired":true,"shares":8043,"price":21.8625,"value":175840.0875,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $21.80 to $22.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":7943465,"source":{"system":"sec-edgar","filing":"0001453687-24-000115","document":"wk-form4_1728079086.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368724000115/wk-form4_1728079086.xml","form_type":"4"}},{"id":1390972,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-04T21:58:13.000Z","date":"2024-10-03","kind":"purchase","planned":false,"acquired":true,"shares":21278,"price":21.1749,"value":450559.5222,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $20.78 to $21.77. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":7935422,"source":{"system":"sec-edgar","filing":"0001453687-24-000115","document":"wk-form4_1728079086.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368724000115/wk-form4_1728079086.xml","form_type":"4"}},{"id":1390971,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-04T21:58:13.000Z","date":"2024-10-03","kind":"purchase","planned":false,"acquired":true,"shares":50489,"price":20.1802,"value":1018878.1178,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $19.77 to $20.70. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":7914144,"source":{"system":"sec-edgar","filing":"0001453687-24-000115","document":"wk-form4_1728079086.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368724000115/wk-form4_1728079086.xml","form_type":"4"}},{"id":1390970,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-04T21:58:13.000Z","date":"2024-10-03","kind":"purchase","planned":false,"acquired":true,"shares":10249,"price":19.0125,"value":194859.1125,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $18.76 to $19.74. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":7863655,"source":{"system":"sec-edgar","filing":"0001453687-24-000115","document":"wk-form4_1728079086.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368724000115/wk-form4_1728079086.xml","form_type":"4"}},{"id":1390969,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-04T21:58:13.000Z","date":"2024-10-03","kind":"purchase","planned":false,"acquired":true,"shares":29847,"price":18.2456,"value":544576.4232,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $17.76 to $18.75. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":7853406,"source":{"system":"sec-edgar","filing":"0001453687-24-000115","document":"wk-form4_1728079086.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368724000115/wk-form4_1728079086.xml","form_type":"4"}},{"id":1390968,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-04T21:58:13.000Z","date":"2024-10-02","kind":"other","planned":false,"acquired":true,"shares":317879,"ownership":{"direct":false,"nature":"By wife"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pro rata distribution for no consideration from TAS Partners LLC to the reporting person or the reporting person's spouse, as the case may be. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pro rata distribution for no consideration from TAS Partners LLC to the reporting person or the reporting person's spouse, as the case may be. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any."}],"balance_after":330695,"source":{"system":"sec-edgar","filing":"0001453687-24-000115","document":"wk-form4_1728079086.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368724000115/wk-form4_1728079086.xml","form_type":"4"}},{"id":1390967,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-04T21:58:13.000Z","date":"2024-10-02","kind":"other","planned":false,"acquired":false,"shares":2119193,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pro rata distribution for no consideration from TAS Partners LLC to the reporting person or the reporting person's spouse, as the case may be. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pro rata distribution for no consideration from TAS Partners LLC to the reporting person or the reporting person's spouse, as the case may be. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any."}],"balance_after":529798,"source":{"system":"sec-edgar","filing":"0001453687-24-000115","document":"wk-form4_1728079086.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368724000115/wk-form4_1728079086.xml","form_type":"4"}},{"id":1390966,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-04T21:58:13.000Z","date":"2024-10-02","kind":"purchase","planned":false,"acquired":true,"shares":5514,"price":17.3779,"value":95821.7406,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $17.17 to $17.50. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":7823559,"source":{"system":"sec-edgar","filing":"0001453687-24-000115","document":"wk-form4_1728079086.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368724000115/wk-form4_1728079086.xml","form_type":"4"}},{"id":1390965,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-04T21:58:13.000Z","date":"2024-10-02","kind":"other","planned":false,"acquired":true,"shares":1801314,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pro rata distribution for no consideration from TAS Partners LLC to the reporting person or the reporting person's spouse, as the case may be. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pro rata distribution for no consideration from TAS Partners LLC to the reporting person or the reporting person's spouse, as the case may be. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any."}],"balance_after":7818045,"source":{"system":"sec-edgar","filing":"0001453687-24-000115","document":"wk-form4_1728079086.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368724000115/wk-form4_1728079086.xml","form_type":"4"}},{"id":1398655,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-27T20:13:36.000Z","date":"2024-09-25","kind":"exercise","planned":false,"acquired":true,"shares":1307,"ownership":{"direct":false,"nature":"By wife"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 20, 2024, the issuer held a special meeting of stockholders (the \"Special Meeting\"). At the Special Meeting, the stockholders of the issuer approved the conversion of the issuer's Series B Non-Voting Convertible Preferred Stock (\"Series B Preferred Stock\") into shares of common stock. On September 25, 2024, the conversion of the majority of the shares of Series B Preferred Stock occurred automatically (the \"Automatic Conversion\"). The remaining shares of Series B Preferred Stock remain subject to certain beneficial ownership limitations described in the issuer's filings with the Securities and Exchange Commission. At the time of the Automatic Conversion, all of the shares of Series B Preferred Stock beneficially owned by the reporting person converted into shares of common stock."}],"balance_after":12816,"source":{"system":"sec-edgar","filing":"0001453687-24-000112","document":"wk-form4_1727468009.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368724000112/wk-form4_1727468009.xml","form_type":"4"}},{"id":1398654,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Non-Voting Convertible Preferred Stock","published_at":"2024-09-27T20:13:36.000Z","date":"2024-09-25","kind":"exercise","planned":false,"acquired":false,"shares":1307,"ownership":{"direct":false,"nature":"By wife"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 20, 2024, the issuer held a special meeting of stockholders (the \"Special Meeting\"). At the Special Meeting, the stockholders of the issuer approved the conversion of the issuer's Series B Non-Voting Convertible Preferred Stock (\"Series B Preferred Stock\") into shares of common stock. On September 25, 2024, the conversion of the majority of the shares of Series B Preferred Stock occurred automatically (the \"Automatic Conversion\"). The remaining shares of Series B Preferred Stock remain subject to certain beneficial ownership limitations described in the issuer's filings with the Securities and Exchange Commission. At the time of the Automatic Conversion, all of the shares of Series B Preferred Stock beneficially owned by the reporting person converted into shares of common stock."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001453687-24-000112","document":"wk-form4_1727468009.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368724000112/wk-form4_1727468009.xml","form_type":"4"}},{"id":1398653,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-27T20:13:36.000Z","date":"2024-09-25","kind":"exercise","planned":false,"acquired":true,"shares":721361,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 20, 2024, the issuer held a special meeting of stockholders (the \"Special Meeting\"). At the Special Meeting, the stockholders of the issuer approved the conversion of the issuer's Series B Non-Voting Convertible Preferred Stock (\"Series B Preferred Stock\") into shares of common stock. On September 25, 2024, the conversion of the majority of the shares of Series B Preferred Stock occurred automatically (the \"Automatic Conversion\"). The remaining shares of Series B Preferred Stock remain subject to certain beneficial ownership limitations described in the issuer's filings with the Securities and Exchange Commission. At the time of the Automatic Conversion, all of the shares of Series B Preferred Stock beneficially owned by the reporting person converted into shares of common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any."}],"balance_after":2648991,"source":{"system":"sec-edgar","filing":"0001453687-24-000112","document":"wk-form4_1727468009.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368724000112/wk-form4_1727468009.xml","form_type":"4"}},{"id":1398652,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Non-Voting Convertible Preferred Stock","published_at":"2024-09-27T20:13:36.000Z","date":"2024-09-25","kind":"exercise","planned":false,"acquired":false,"shares":721361,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 20, 2024, the issuer held a special meeting of stockholders (the \"Special Meeting\"). At the Special Meeting, the stockholders of the issuer approved the conversion of the issuer's Series B Non-Voting Convertible Preferred Stock (\"Series B Preferred Stock\") into shares of common stock. On September 25, 2024, the conversion of the majority of the shares of Series B Preferred Stock occurred automatically (the \"Automatic Conversion\"). The remaining shares of Series B Preferred Stock remain subject to certain beneficial ownership limitations described in the issuer's filings with the Securities and Exchange Commission. At the time of the Automatic Conversion, all of the shares of Series B Preferred Stock beneficially owned by the reporting person converted into shares of common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001453687-24-000112","document":"wk-form4_1727468009.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368724000112/wk-form4_1727468009.xml","form_type":"4"}},{"id":1398651,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-27T20:13:36.000Z","date":"2024-09-25","kind":"exercise","planned":false,"acquired":true,"shares":1636832,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 20, 2024, the issuer held a special meeting of stockholders (the \"Special Meeting\"). At the Special Meeting, the stockholders of the issuer approved the conversion of the issuer's Series B Non-Voting Convertible Preferred Stock (\"Series B Preferred Stock\") into shares of common stock. On September 25, 2024, the conversion of the majority of the shares of Series B Preferred Stock occurred automatically (the \"Automatic Conversion\"). The remaining shares of Series B Preferred Stock remain subject to certain beneficial ownership limitations described in the issuer's filings with the Securities and Exchange Commission. At the time of the Automatic Conversion, all of the shares of Series B Preferred Stock beneficially owned by the reporting person converted into shares of common stock."}],"balance_after":6016731,"source":{"system":"sec-edgar","filing":"0001453687-24-000112","document":"wk-form4_1727468009.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368724000112/wk-form4_1727468009.xml","form_type":"4"}},{"id":1398650,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Non-Voting Convertible Preferred Stock","published_at":"2024-09-27T20:13:36.000Z","date":"2024-09-25","kind":"exercise","planned":false,"acquired":false,"shares":1636832,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 20, 2024, the issuer held a special meeting of stockholders (the \"Special Meeting\"). At the Special Meeting, the stockholders of the issuer approved the conversion of the issuer's Series B Non-Voting Convertible Preferred Stock (\"Series B Preferred Stock\") into shares of common stock. On September 25, 2024, the conversion of the majority of the shares of Series B Preferred Stock occurred automatically (the \"Automatic Conversion\"). The remaining shares of Series B Preferred Stock remain subject to certain beneficial ownership limitations described in the issuer's filings with the Securities and Exchange Commission. At the time of the Automatic Conversion, all of the shares of Series B Preferred Stock beneficially owned by the reporting person converted into shares of common stock."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001453687-24-000112","document":"wk-form4_1727468009.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368724000112/wk-form4_1727468009.xml","form_type":"4"}},{"id":1399102,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-26T22:15:52.000Z","date":"2024-09-26","kind":"purchase","planned":false,"acquired":true,"shares":2400,"price":30.87,"value":74088.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $30.80 to $30.90 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":3796764,"source":{"system":"sec-edgar","filing":"0001415889-24-024003","document":"form4-09262024_100948.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000141588924024003/form4-09262024_100948.xml","form_type":"4"}},{"id":1399101,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-26T22:15:52.000Z","date":"2024-09-26","kind":"purchase","planned":false,"acquired":true,"shares":4070,"price":30.1,"value":122507.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $29.75 to $30.63 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":3794364,"source":{"system":"sec-edgar","filing":"0001415889-24-024003","document":"form4-09262024_100948.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000141588924024003/form4-09262024_100948.xml","form_type":"4"}},{"id":1399100,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-26T22:15:52.000Z","date":"2024-09-26","kind":"purchase","planned":false,"acquired":true,"shares":18999,"price":29.13,"value":553440.87,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $28.69 to $29.68 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":3790294,"source":{"system":"sec-edgar","filing":"0001415889-24-024003","document":"form4-09262024_100948.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000141588924024003/form4-09262024_100948.xml","form_type":"4"}},{"id":1399099,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-26T22:15:52.000Z","date":"2024-09-26","kind":"purchase","planned":false,"acquired":true,"shares":24531,"price":28.16,"value":690792.96,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $27.68 to $28.66 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":3771295,"source":{"system":"sec-edgar","filing":"0001415889-24-024003","document":"form4-09262024_100948.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000141588924024003/form4-09262024_100948.xml","form_type":"4"}},{"id":1399098,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-26T22:15:52.000Z","date":"2024-09-24","kind":"other","planned":false,"acquired":true,"shares":186134,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents the acquisition of the shares from TAS, as more specifically described in Footnote (1) herein."}],"balance_after":186134,"source":{"system":"sec-edgar","filing":"0001415889-24-024003","document":"form4-09262024_100948.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000141588924024003/form4-09262024_100948.xml","form_type":"4"}},{"id":1399097,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-26T22:15:52.000Z","date":"2024-09-24","kind":"other","planned":false,"acquired":true,"shares":1054759,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents the acquisition of the shares from TAS, as more specifically described in Footnote (1) herein."}],"balance_after":3746764,"source":{"system":"sec-edgar","filing":"0001415889-24-024003","document":"form4-09262024_100948.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000141588924024003/form4-09262024_100948.xml","form_type":"4"}},{"id":1399096,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-09-26T22:15:52.000Z","date":"2024-09-24","kind":"other","planned":false,"acquired":false,"shares":1240893,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a distribution in kind, for no additional consideration, by TAS Partners, LLC (\"TAS\") to the Reporting Person and his spouse."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held by TAS. The Reporting Person is the sole managing member of TAS and, as such, has sole voting and dispositive power over the shares held by TAS. The Reporting Person disclaims beneficial ownership of the shares held by TAS except to the extent of his pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."}],"balance_after":310223,"source":{"system":"sec-edgar","filing":"0001415889-24-024003","document":"form4-09262024_100948.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000141588924024003/form4-09262024_100948.xml","form_type":"4"}},{"id":1428061,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-20T23:10:20.000Z","date":"2024-08-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23168,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the \"Unvested Option\") became fully vested and exercisable (the \"Vested Option\"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Option will vest in full on the earlier of (a) June 04, 2025 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date."}],"balance_after":0,"derivative":{"exercise_price":30.52,"expiration_date":"2034-06-03","underlying":"Common Stock","underlying_shares":23168},"source":{"system":"sec-edgar","filing":"0001415889-24-021765","document":"form4-08202024_110817.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000141588924021765/form4-08202024_110817.xml","form_type":"4"}},{"id":1428060,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-20T23:10:20.000Z","date":"2024-08-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12535,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the \"Unvested Option\") became fully vested and exercisable (the \"Vested Option\"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Company Stock Option (\"Option\") is fully vested."}],"balance_after":0,"derivative":{"exercise_price":56.47,"expiration_date":"2033-05-31","underlying":"Common Stock","underlying_shares":12535},"source":{"system":"sec-edgar","filing":"0001415889-24-021765","document":"form4-08202024_110817.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000141588924021765/form4-08202024_110817.xml","form_type":"4"}},{"id":1428059,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-20T23:10:20.000Z","date":"2024-08-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17550,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the \"Unvested Option\") became fully vested and exercisable (the \"Vested Option\"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Company Stock Option (\"Option\") is fully vested."}],"balance_after":0,"derivative":{"exercise_price":24.49,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":17550},"source":{"system":"sec-edgar","filing":"0001415889-24-021765","document":"form4-08202024_110817.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000141588924021765/form4-08202024_110817.xml","form_type":"4"}},{"id":1428058,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-20T23:10:20.000Z","date":"2024-08-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9996,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the \"Unvested Option\") became fully vested and exercisable (the \"Vested Option\"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Company Stock Option (\"Option\") is fully vested."}],"balance_after":0,"derivative":{"exercise_price":64.79,"expiration_date":"2031-06-16","underlying":"Common Stock","underlying_shares":9996},"source":{"system":"sec-edgar","filing":"0001415889-24-021765","document":"form4-08202024_110817.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000141588924021765/form4-08202024_110817.xml","form_type":"4"}},{"id":1428057,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-20T23:10:20.000Z","date":"2024-08-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the \"Unvested Option\") became fully vested and exercisable (the \"Vested Option\"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Company Stock Option (\"Option\") is fully vested."}],"balance_after":0,"derivative":{"exercise_price":22.96,"expiration_date":"2030-06-18","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001415889-24-021765","document":"form4-08202024_110817.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000141588924021765/form4-08202024_110817.xml","form_type":"4"}},{"id":1428056,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-20T23:10:20.000Z","date":"2024-08-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":90000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the \"Unvested Option\") became fully vested and exercisable (the \"Vested Option\"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Company Stock Option (\"Option\") is fully vested."}],"balance_after":0,"derivative":{"exercise_price":15.72,"expiration_date":"2029-12-05","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001415889-24-021765","document":"form4-08202024_110817.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000141588924021765/form4-08202024_110817.xml","form_type":"4"}},{"id":1428055,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-20T23:10:20.000Z","date":"2024-08-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":24000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the \"Unvested Option\") became fully vested and exercisable (the \"Vested Option\"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Company Stock Option (\"Option\") is fully vested."}],"balance_after":0,"derivative":{"exercise_price":15,"expiration_date":"2029-06-26","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001415889-24-021765","document":"form4-08202024_110817.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000141588924021765/form4-08202024_110817.xml","form_type":"4"}},{"id":1428054,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-20T23:10:20.000Z","date":"2024-08-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4288,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the \"Unvested Option\") became fully vested and exercisable (the \"Vested Option\"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Company Stock Option (\"Option\") is fully vested."}],"balance_after":0,"derivative":{"exercise_price":7.76,"expiration_date":"2029-04-11","underlying":"Common Stock","underlying_shares":4288},"source":{"system":"sec-edgar","filing":"0001415889-24-021765","document":"form4-08202024_110817.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000141588924021765/form4-08202024_110817.xml","form_type":"4"}},{"id":1428053,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-20T23:10:20.000Z","date":"2024-08-16","kind":"other","planned":false,"acquired":false,"shares":42873,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the \"Issuer\" or the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Eli Lilly and Company, an Indiana corporation (the \"Parent\"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the \"Merger\") with the Company surviving the Merger as a wholly owned subsidiary of the Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) Upon the closing (the \"Closing\") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share (\"Common Stock\"), was either (x) purchased by Purchaser for $57.00 per share (the \"Offer Price\"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-24-021765","document":"form4-08202024_110817.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000141588924021765/form4-08202024_110817.xml","form_type":"4"}},{"id":1428052,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-20T23:10:20.000Z","date":"2024-08-16","kind":"other","planned":false,"acquired":false,"shares":2768893,"ownership":{"direct":false,"nature":"See TAS Partners LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the \"Issuer\" or the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Eli Lilly and Company, an Indiana corporation (the \"Parent\"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the \"Merger\") with the Company surviving the Merger as a wholly owned subsidiary of the Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) Upon the closing (the \"Closing\") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share (\"Common Stock\"), was either (x) purchased by Purchaser for $57.00 per share (the \"Offer Price\"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person is the manager of TAS Partners LLC and has sole voting and dispositive power over such shares."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-24-021765","document":"form4-08202024_110817.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000141588924021765/form4-08202024_110817.xml","form_type":"4"}},{"id":1428051,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-20T23:10:20.000Z","date":"2024-08-16","kind":"other","planned":false,"acquired":false,"shares":4608052,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the \"Issuer\" or the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Eli Lilly and Company, an Indiana corporation (the \"Parent\"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the \"Merger\") with the Company surviving the Merger as a wholly owned subsidiary of the Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) Upon the closing (the \"Closing\") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share (\"Common Stock\"), was either (x) purchased by Purchaser for $57.00 per share (the \"Offer Price\"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-24-021765","document":"form4-08202024_110817.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000141588924021765/form4-08202024_110817.xml","form_type":"4"}},{"id":1434069,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:43:58.000Z","date":"2024-08-12","kind":"purchase","planned":false,"acquired":true,"shares":8016,"price":12.7205,"value":101967.528,"ownership":{"direct":false,"nature":"By wife"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $12.48 to $13.05. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":11509,"source":{"system":"sec-edgar","filing":"0001453687-24-000106","document":"wk-form4_1723668232.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368724000106/wk-form4_1723668232.xml","form_type":"4"}},{"id":1458983,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Non-Voting Convertible Preferred Stock","published_at":"2024-07-05T20:02:09.000Z","date":"2024-07-02","kind":"grant","planned":false,"acquired":true,"shares":1307,"price":20,"value":26140.0,"ownership":{"direct":false,"nature":"By wife"},"balance_after":1307,"source":{"system":"sec-edgar","filing":"0001453687-24-000095","document":"wk-form4_1720209722.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368724000095/wk-form4_1720209722.xml","form_type":"4"}},{"id":1458982,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Non-Voting Convertible Preferred Stock","published_at":"2024-07-05T20:02:09.000Z","date":"2024-07-02","kind":"grant","planned":false,"acquired":true,"shares":721361,"price":20,"value":14427220.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any."}],"balance_after":721361,"source":{"system":"sec-edgar","filing":"0001453687-24-000095","document":"wk-form4_1720209722.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368724000095/wk-form4_1720209722.xml","form_type":"4"}},{"id":1458981,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Non-Voting Convertible Preferred Stock","published_at":"2024-07-05T20:02:09.000Z","date":"2024-07-02","kind":"grant","planned":false,"acquired":true,"shares":1636832,"price":20,"value":32736640.0,"ownership":{"direct":true},"balance_after":1636832,"source":{"system":"sec-edgar","filing":"0001453687-24-000095","document":"wk-form4_1720209722.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368724000095/wk-form4_1720209722.xml","form_type":"4"}},{"id":1471081,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-24T20:30:20.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":11760,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/3rd of the shares subject to the option will vest on June 20, 2025, and the balance will vest in equal monthly installments thereafter over the next 24 months, subject in each case to the continuous service of the Reporting Person to the Issuer through the applicable vesting date."}],"balance_after":11760,"derivative":{"exercise_price":16.8,"expiration_date":"2034-06-19","underlying":"Common Stock","underlying_shares":11760},"source":{"system":"sec-edgar","filing":"0001415889-24-017984","document":"form4-06242024_080610.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000141588924017984/form4-06242024_080610.xml","form_type":"4"}},{"id":1471080,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-06-24T20:30:20.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":1551116,"ownership":{"direct":false,"nature":"By LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in exchange for 2,902,429 shares of common stock of Tectonic on the same terms and conditions as set forth in footnote (1) herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held by TAS Partners, LLC (\"TAS\"). The Reporting Person is the sole managing member of TAS and, as such, has sole voting and dispositive power over the shares held by TAS. The Reporting Person disclaims beneficial ownership of the shares held by TAS except to the extent of his pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."}],"balance_after":1551116,"source":{"system":"sec-edgar","filing":"0001415889-24-017984","document":"form4-06242024_080610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000141588924017984/form4-06242024_080610.xml","form_type":"4"}},{"id":1471079,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-06-24T20:30:20.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":2692005,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for 5,037,245 shares of common stock of Tectonic Therapeutic, Inc., a Delaware corporation (\"Tectonic\"), pursuant to an Agreement and Plan of Merger dated as of January 30, 2024 (the \"Merger Agreement\") by and among AVROBIO, Inc., a Delaware corporation (\"AVROBIO\"), Tectonic and Alpine Merger Subsidiary, Inc., a direct, wholly owned subsidiary of AVROBIO (the \"Merger Sub\"). Under the terms of the Merger Agreement, on June 20, 2024, Merger Sub merged with and into Tectonic (the \"Merger\"), with Tectonic surviving the Merger as a wholly owned subsidiary of AVROBIO. Upon the closing of the Merger, each share of Tectonic common stock was converted into the right to receive 0.534419990 shares of the Issuer's common stock, after giving effect to a reverse stock split of the Issuer's common stock of 1-for-12. Subsequent to the Merger, the name of the Issuer was changed from AVROBIO, Inc. to Tectonic Therapeutic, Inc."}],"balance_after":2692005,"source":{"system":"sec-edgar","filing":"0001415889-24-017984","document":"form4-06242024_080610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000141588924017984/form4-06242024_080610.xml","form_type":"4"}},{"id":1490629,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-06-05T23:14:20.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":23168,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on the earlier of (a) June 04, 2025 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date."}],"balance_after":23168,"derivative":{"exercise_price":30.52,"expiration_date":"2034-06-03","underlying":"Common Stock","underlying_shares":23168},"source":{"system":"sec-edgar","filing":"0001415889-24-015670","document":"form4-06052024_110616.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000141588924015670/form4-06052024_110616.xml","form_type":"4"}},{"id":1543983,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-11T01:40:19.000Z","date":"2024-04-08","kind":"exercise","planned":false,"acquired":true,"shares":826169,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 27, 2024, the issuer held a special meeting of stockholders (the \"Special Meeting\"). At the Special Meeting, the stockholders of the issuer approved a 1-for-30 reverse stock split (the \"Reverse Stock Split\") of the issuer's common stock (\"Common Stock\") and the conversion of the issuer's Series A Non-Voting Convertible Preferred Stock (\"Series A Preferred Stock\") into shares of Common Stock. On April 8, 2024, the conversion of the majority of the shares of Series A Preferred Stock occurred automatically (the \"Automatic Conversion\"). The remaining shares of Series A Preferred Stock remain subject to certain beneficial ownership limitations described in the issuer's filings with the Securities and Exchange Commission. At the time of the Automatic Conversion, all of the reporting person's shares of Series A Preferred Stock converted into shares of Common Stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On April 4, 2024, the issuer effected the \"Reverse Stock Split\".  The amount of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any."}],"balance_after":1927630,"source":{"system":"sec-edgar","filing":"0001453687-24-000063","document":"wk-form4_1712799609.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368724000063/wk-form4_1712799609.xml","form_type":"4"}},{"id":1543982,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Non-Voting Convertible Preferred Stock","published_at":"2024-04-11T01:40:19.000Z","date":"2024-04-08","kind":"exercise","planned":false,"acquired":false,"shares":24785.081,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 27, 2024, the issuer held a special meeting of stockholders (the \"Special Meeting\"). At the Special Meeting, the stockholders of the issuer approved a 1-for-30 reverse stock split (the \"Reverse Stock Split\") of the issuer's common stock (\"Common Stock\") and the conversion of the issuer's Series A Non-Voting Convertible Preferred Stock (\"Series A Preferred Stock\") into shares of Common Stock. On April 8, 2024, the conversion of the majority of the shares of Series A Preferred Stock occurred automatically (the \"Automatic Conversion\"). The remaining shares of Series A Preferred Stock remain subject to certain beneficial ownership limitations described in the issuer's filings with the Securities and Exchange Commission. At the time of the Automatic Conversion, all of the reporting person's shares of Series A Preferred Stock converted into shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001453687-24-000063","document":"wk-form4_1712799609.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368724000063/wk-form4_1712799609.xml","form_type":"4"}},{"id":1543981,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-11T01:40:19.000Z","date":"2024-04-08","kind":"exercise","planned":false,"acquired":true,"shares":4130846,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 27, 2024, the issuer held a special meeting of stockholders (the \"Special Meeting\"). At the Special Meeting, the stockholders of the issuer approved a 1-for-30 reverse stock split (the \"Reverse Stock Split\") of the issuer's common stock (\"Common Stock\") and the conversion of the issuer's Series A Non-Voting Convertible Preferred Stock (\"Series A Preferred Stock\") into shares of Common Stock. On April 8, 2024, the conversion of the majority of the shares of Series A Preferred Stock occurred automatically (the \"Automatic Conversion\"). The remaining shares of Series A Preferred Stock remain subject to certain beneficial ownership limitations described in the issuer's filings with the Securities and Exchange Commission. At the time of the Automatic Conversion, all of the reporting person's shares of Series A Preferred Stock converted into shares of Common Stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On April 4, 2024, the issuer effected the \"Reverse Stock Split\".  The amount of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split."}],"balance_after":4379899,"source":{"system":"sec-edgar","filing":"0001453687-24-000063","document":"wk-form4_1712799609.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368724000063/wk-form4_1712799609.xml","form_type":"4"}},{"id":1543980,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Non-Voting Convertible Preferred Stock","published_at":"2024-04-11T01:40:19.000Z","date":"2024-04-08","kind":"exercise","planned":false,"acquired":false,"shares":123925.407,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 27, 2024, the issuer held a special meeting of stockholders (the \"Special Meeting\"). At the Special Meeting, the stockholders of the issuer approved a 1-for-30 reverse stock split (the \"Reverse Stock Split\") of the issuer's common stock (\"Common Stock\") and the conversion of the issuer's Series A Non-Voting Convertible Preferred Stock (\"Series A Preferred Stock\") into shares of Common Stock. On April 8, 2024, the conversion of the majority of the shares of Series A Preferred Stock occurred automatically (the \"Automatic Conversion\"). The remaining shares of Series A Preferred Stock remain subject to certain beneficial ownership limitations described in the issuer's filings with the Securities and Exchange Commission. At the time of the Automatic Conversion, all of the reporting person's shares of Series A Preferred Stock converted into shares of Common Stock."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001453687-24-000063","document":"wk-form4_1712799609.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368724000063/wk-form4_1712799609.xml","form_type":"4"}},{"id":1558788,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-03-28T21:11:38.000Z","date":"2024-03-18","kind":"purchase","planned":false,"acquired":true,"shares":800,"price":0.61,"value":488.0,"ownership":{"direct":false,"nature":"By wife"},"balance_after":104818,"source":{"system":"sec-edgar","filing":"0001453687-24-000050","document":"wk-form4_1711660282.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368724000050/wk-form4_1711660282.xml","form_type":"4"}},{"id":1558787,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-03-28T21:11:38.000Z","date":"2024-03-15","kind":"purchase","planned":false,"acquired":true,"shares":1200,"price":0.56,"value":672.0,"ownership":{"direct":false,"nature":"By wife"},"balance_after":104018,"source":{"system":"sec-edgar","filing":"0001453687-24-000050","document":"wk-form4_1711660282.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368724000050/wk-form4_1711660282.xml","form_type":"4"}},{"id":1558786,"issuer":{"id":6015,"kind":"organization","name":"Cartesian Therapeutics, Inc."},"owners":[{"id":39790,"kind":"person","name":"SPRINGER TIMOTHY A","position":1,"cik":"0001055624","reported_name":"SPRINGER TIMOTHY A","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-03-28T21:11:38.000Z","date":"2024-03-14","kind":"purchase","planned":false,"acquired":true,"shares":2000,"price":0.5305,"value":1061.0,"ownership":{"direct":false,"nature":"By wife"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $0.52 to $0.54. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":102818,"source":{"system":"sec-edgar","filing":"0001453687-24-000050","document":"wk-form4_1711660282.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1055624/000145368724000050/wk-form4_1711660282.xml","form_type":"4"}}],"next_cursor":"2024-03-28T21:11:38.000000Z,1558786"}